References

Membranous nephropathy

10.3390/jcm14030761 · 2025 · External reference

Ofatumumab in rituximab-resistant and rituximab-intolerant patients with primary membranous nephropathy: a case series

10.1053/j.ajkd.2023.08.010 · 2024 · External reference

Obinutuzumab in refractory membranous nephropathy: a case series

10.1016/j.xkme.2024.100853 · 2024 · External reference

Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy

10.1093/ckj/sfaf026 · 2025 · External reference

Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study

2025 · External reference

Experience with new anti-CD20 monoclonal antibodies for immune-mediated glomerulopathies in a tertiary hospital

2025 · External reference

Membranous nephropathy: recent travels and new roads ahead

10.1038/ki.2010.34 · 2010 · External reference

Membranous nephropathy: integrating basic science into improved clinical management

10.1016/j.kint.2016.09.048 · 2017 · External reference

KDIGO 2021 clinical practice guideline for the management of glomerular diseases

2021 · External reference

Antigens in membranous nephropathy: discovery and clinical implications

10.1038/s41581-025-00980-z · 2025 · External reference

The evolution of the therapeutic approach to membranous nephropathy

10.1093/ndt/gfaa014 · 2021 · External reference

How to choose the right treatment for membranous nephropathy

10.3390/medicina59111997 · 2023 · External reference

A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy

10.1056/nejm198901053200102 · 1989 · External reference

A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy

10.1681/asn.v93444 · 1998 · External reference

Membranous nephropathy treatment standard

10.1093/ndt/gfad225 · 2024 · External reference

10.1007/s11255-025-04549-4

10.1007/s11255-025-04549-4 · 2025 · External reference

Characterization of a human B lymphocyte-specific antigen

10.4049/jimmunol.125.4.1678 · 1980 · External reference

The MS4A family: counting past 1, 2 and 3

10.1038/icb.2015.48 · 2016 · External reference

Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1)

10.4049/jimmunol.142.7.2560 · 1989 · External reference

Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes

10.1016/s0021-9258(19)81618-6 · 1988 · External reference

Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes

10.1083/jcb.121.5.1121 · 1993 · External reference

CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins

10.1074/jbc.m800784200 · 2008 · External reference

Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY

10.4049/jimmunol.157.7.2939 · 1996 · External reference

B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets

2018 · External reference

Mechanisms of killing by anti-CD20 monoclonal antibodies

10.1016/j.molimm.2007.06.151 · 2007 · External reference

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

10.1182/blood.v84.8.2457.2457 · 1994 · External reference

CD20: a regulator of cell-cycle progression of B lymphocytes

10.1016/0167-5699(94)90276-3 · 1994 · External reference

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

10.1038/sj.onc.1206939 · 2003 · External reference

CD20 deficiency in humans results in impaired T cell-independent antibody responses

10.1172/jci40231 · 2010 · External reference

Mouse CD20 expression and function

10.1093/intimm/dxh009 · 2004 · External reference

Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going?

10.3389/fimmu.2017.01245 · 2017 · External reference

Mechanisms of action of CD20 antibodies

2012 · External reference

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

10.4161/mabs.22771 · 2013 · External reference

Complement-dependent activity of CD20-specific IgG correlates with bivalent antigen binding and C1q binding strength

2020 · External reference

Cellular cytotoxicity of next-generation CD20 monoclonal antibodies

10.1158/2326-6066.cir-18-0319 · 2018 · External reference

The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy

10.1016/j.kint.2020.10.014 · 2021 · External reference

Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial

10.1681/asn.2020071091 · 2021 · External reference

Rituximab in idiopathic membranous nephropathy

10.1681/asn.2012020181 · 2012 · External reference

Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy

10.1681/asn.2014070640 · 2015 · External reference

Rituximab or cyclosporine in the treatment of membranous nephropathy

10.1056/nejmoa1814427 · 2019 · External reference

Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy

10.2215/cjn.01180307 · 2007 · External reference

Efficacy and safety of a B-cell-driven rituximab regimen for the treatment of refractory idiopathic membranous nephropathy

10.1186/s40360-025-00954-8 · 2025 · External reference

Artificial intelligence-based personalised rituximab treatment protocol in membranous nephropathy (iRITUX): protocol for a multicentre randomised control trial

10.1136/bmjopen-2024-093920 · 2025 · External reference

Novel treatment options in rituximab-resistant membranous nephropathy patients

10.1016/j.intimp.2022.108635 · 2022 · External reference

Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab

10.3389/fimmu.2019.03069 · 2020 · External reference

Cross-reactivity of antibodies to rituximab with other therapeutic anti-CD20 antibodies

10.4049/jimmunol.2300647 · 2024 · External reference

New treatments in membranous glomerulopathy – from the pitfalls of rituximab to a new era of biological treatments

2020 · External reference

Rituximab exhibits altered pharmacokinetics in patients with membranous nephropathy

10.1177/1060028018803587 · 2019 · External reference

Membranous nephropathy

10.1038/s41572-021-00303-z · 2021 · External reference

Rituximab for the treatment of membranous nephropathy: a single-center experience

10.5414/cnp88fx07 · 2017 · External reference

Successful treatment of patients with refractory PLA2R-associated membranous nephropathy with obinutuzumab: a report of 3 cases

10.1053/j.ajkd.2020.02.444 · 2020 · External reference

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

10.1182/blood-2009-06-225979 · 2010 · External reference

Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models

10.1158/1535-7163.mct-12-1182 · 2013 · External reference

The future of anti-CD20 monoclonal antibodies: are we making progress?

10.1182/blood-2010-07-298356 · 2011 · External reference

Efficacy and safety of obinutuzumab in active lupus nephritis

10.1056/nejmoa2410965 · 2025 · External reference

Targeting B cells and plasma cells in glomerular diseases: translational perspectives

10.1681/asn.2017040367 · 2018 · External reference

Obinutuzumab as initial or second-line therapy in patients with primary membranous nephropathy

10.1016/j.ekir.2024.05.004 · 2024 · External reference

Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy

10.2215/cjn.0000000000000555 · 2024 · External reference

Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy

10.1093/ndt/gfae230 · 2025 · External reference

Additive obinutuzumab achieves high remission rates in rituximab-refractory membranous nephropathy

2025 · External reference

Obinutuzumab is effective for the treatment of refractory membranous nephropathy

10.1016/j.ekir.2020.06.030 · 2020 · External reference

Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases

10.1186/s12882-022-02761-3 · 2022 · External reference

Obinutuzumab is effective as an initial treatment for PLA2R-associated primary membranous nephropathy: a retrospective, single-center trial

10.2147/dddt.s527661 · 2025 · External reference

Observation of the efficacy and safety of obinutuzumab in the treatment of refractory idiopathic membranous nephropathy

10.1007/s11255-025-04407-3 · 2025 · External reference

Anti-CD20 monoclonal antibodies: reviewing a revolution

10.1080/21645515.2018.1508624 · 2018 · External reference

The development of ofatumumab, a fully human anti-CD20 monoclonal antibody for practical use in relapsing multiple sclerosis treatment

10.1007/s40120-023-00518-0 · 2023 · External reference

Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness

10.1136/bcr-2019-232896 · 2020 · External reference

Case Report: Subcutaneous ofatumumab for patients with immunosuppressant-dependent or ineffective primary membranous nephropathy

2025 · External reference

Obinutuzumab and ofatumumab are more effective than rituximab in the treatment of membranous nephropathy patients with anti-rituximab antibodies

10.1016/j.ekir.2024.12.012 · 2024 · External reference

Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives

10.3389/fimmu.2022.1024068 · 2022 · External reference

Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma

10.1093/annonc/mdq027 · 2010 · External reference

Successful treatment of PLA2R1-antibody positive membranous nephropathy with ocrelizumab

10.1007/s40620-020-00874-2 · 2021 · External reference

Systematic review of safety and efficacy of second- and third-generation CD20-targeting biologics in treating immune-mediated disorders

10.3389/fimmu.2021.788830 · 2022 · External reference

Efficacy and safety of zuberitamab in the treatment of primary membranous nephropathy: an observational study

10.3389/fimmu.2025.1741564 · 2026 · External reference

Anti-CD20 should be the first-line treatment in high-risk membranous nephropathy

10.1093/ckj/sfad075 · 2023 · External reference

Treatment of membranous nephropathy: time for a paradigm shift

10.1038/nrneph.2017.92 · 2017 · External reference

Pathophysiological advances in membranous nephropathy: time for a shift in patient's care

10.1016/s0140-6736(15)60731-0 · 2015 · External reference

The role of anti-PLA2R and anti-THSD7A antibodies in the pathogenesis and diagnostics of primary membranous nephropathy: a review of current knowledge for clinical practice

10.3390/ijerph19095301 · 2022 · External reference

A proposal for a serology-based approach to membranous nephropathy

10.1681/asn.2016070776 · 2017 · External reference

Anti-PLA2R antibody levels and clinical risk factors for treatment nonresponse in membranous nephropathy

10.2215/cjn.0000000000000237 · 2023 · External reference

Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: a single-centre study over 14 years

10.1371/journal.pone.0173201 · 2017 · External reference

B cell dysregulation and depletion therapy in primary membranous nephropathy: prospects and potential challenges

10.1016/j.intimp.2024.112769 · 2024 · External reference

B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab

10.1016/j.kint.2017.01.012 · 2017 · External reference

The role of B lymphocyte subsets in nephrotic syndrome: functions, mechanisms, clinical significance and future perspectives

10.3389/fimmu.2025.1598197 · 2025 · External reference

Circulating (CD3(−)CD19(+)CD20(−)IgD(−)CD27(high)CD38(high)) plasmablasts: a promising cellular biomarker for immune activity for anti-PLA2R1 related membranous nephropathy?

10.1155/2016/7651024 · 2016 · External reference

Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up

10.1681/asn.2016040449 · 2017 · External reference

Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia

10.1001/jamanetworkopen.2018.4169 · 2018 · External reference

Obinutuzumab in kidney transplantation: past, present, and future

10.5500/wjt.v15.i4.108982 · 2025 · External reference

Obinutuzumab in rituximab-resistant and recurrent membranous nephropathy: a case-series

10.1007/s40620-025-02224-6 · 2025 · External reference

Chimeric autoantibody receptor T cells clonally eliminate B cells producing autoantibodies against IFN-γ

10.1126/sciimmunol.adm8186 · 2025 · External reference

Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris

10.1172/jci138416 · 2020 · External reference

An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells

10.1016/j.kint.2024.01.021 · 2024 · External reference

Preclinical evaluation of antigen-specific B-cell depletion for phospholipase A2 receptor membranous nephropathy with chimeric autoantibody receptor T cells

10.1016/j.kint.2025.09.028 · 2026 · External reference